Skip to main content

Table 1 Effects of roxadustat on bone histomorphometric parameters

From: Roxadustat promotes osteoblast differentiation and prevents estrogen deficiency-induced bone loss by stabilizing HIF-1α and activating the Wnt/β-catenin signaling pathway

Parameters

Sham

OVX

OVX + Roxadustat

Trabecular

   

 BMD (g/cm3)

0.96 ± 0.07

0.55 ± 0.05**

0.63 ± 0.05**#

 BV/TV (%)

75.88 ± 7.21

37.51 ± 4.93**

44.80 ± 3.61**#

 Tb.N (1/mm)

6.79 ± 0.46

4.07 ± 0.33**

4.75 ± 0.49**#

 Tb.Th (mm)

0.112 ± 0.005

0.092 ± 0.008**

0.095 ± 0.003**

 Tb.Sp (mm)

0.045 ± 0.004

0.157 ± 0.009**

0.146 ± 0.006**#

 Oc.S/BS (%)

4.22 ± 1.30

11.93 ± 2.55**

8.63 ± 2.27**#

 N.Oc/BS (/mm)

1.65 ± 0.48

5.92 ± 1.39**

4.16 ± 0.73**##

 Ob.S/BS (%)

5.95 ± 1.31

13.11 ± 3.97**

18.12 ± 5.06**#

 N.Ob/BS (/mm)

6.40 ± 1.86

10.26 ± 2.60*

14.19 ± 3.19**#

 MAR (μm/d)

1.27 ± 0.12

1.35 ± 0.17

1.67 ± 0.17**##

 BFR/BS (μm3/μm2/d)

0.22 ± 0.04

0.34 ± 0.08**

0.44 ± 0.07**#

Cortical

   

 BMD (g/cm3)

2.02 ± 0.03

1.98 ± 0.04

2.00 ± 0.04

 %Ct.Ar (%)

44.14 ± 3.02

32.46 ± 1.20**

33.38 ± 1.19**

 Ct.Th (mm)

0.45 ± 0.04

0.32 ± 0.02**

0.35 ± 0.02**

  1. Data are presented as the mean ± SD. n = 8 in each group. *P < 0.05, **P < 0.01, compared with the sham group; #P < 0.05, ##P < 0.01, compared with the OVX group. %Ct.Ar = cortical area/total tissue area. MAR = double-labeled width/labeled time interval. BFR/BS = (double-labeled surface + single-labeled surface/2)*MAR/trabecular perimeter